Range Impact (RNGE) 10-Q 14 Feb 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Dec. 31, 2019	Feb. 13, 2020
Document And Entity Information [Abstract]
Entity Registrant Name	Vitality Biopharma, Inc.
Entity Central Index Key	0001438943
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		50,840,147
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Current Assets
Cash	$ 3,123,400	$ 5,982,741
Accounts receivable, net		19,360
Prepaid expense and other current assets	13,195	50,547
Total current assets	3,136,595	6,052,648
Deposits	32,662	22,662
Operating lease right-of-use asset	154,580
Total Assets	3,323,837	6,075,310
Current Liabilities
Accounts payable and accrued liabilities	977,022	716,671
Accounts payable - related party		5,200
Advance	296,653	296,653
Operating lease liability, current portion	115,852
Derivative liability	85	35,710
Total current liabilities	1,389,612	1,054,234
Operating lease liability, net of current portion	34,619
Total liabilities	1,424,231	1,054,234
Commitments and contingencies
Stockholders' Equity
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 50,840,147 and 52,290,147 shares issued and outstanding, respectively	50,640	52,090
Additional paid-in-capital	47,644,493	47,150,489
Accumulated deficit	(45,795,527)	(42,181,503)
Total stockholders' equity	1,899,606	5,021,076
Total Liabilities and Stockholders' Equity	$ 3,323,837	$ 6,075,310

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Mar. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	50,840,147	52,290,147
Common stock, shares outstanding	50,840,147	52,290,147

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenue
Operating expenses:
General and administrative	506,926	839,522	2,094,026	1,963,497
Research and development	241,840	96,340	864,849	1,162,011
Rent - related party		7,800		23,400
Total operating expenses	748,766	943,662	2,958,875	3,148,908
Loss from operations	(748,766)	(943,662)	(2,958,875)	(3,148,908)
Other income (expense)
Change in fair value of derivative liability	1,711	162,908	35,625	100,559
Interest earned	529		529
Other income			23,524
Total other income, net	2,240	162,908	59,678	100,559
Loss from continuing operations	(746,526)	(780,754)	(2,899,197)	(3,048,349)
Loss from discontinued operations	(48,769)	(427,817)	(714,827)	(516,238)
Net loss	$ (795,295)	$ (1,208,571)	$ (3,614,024)	$ (3,564,587)
Net loss per common share
Loss from continuing operations	$ (0.01)	$ (0.02)	$ (0.06)	$ (0.11)
Loss from discontinued operations	$ 0	$ (0.01)	$ (0.01)	$ (0.02)
Weighted average number of common shares outstanding Basic and diluted	50,840,147	32,741,120	51,773,420	26,559,259

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in-Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Mar. 31, 2018	$ 24,075	$ 22,343,135	$ (22,044,936)	$ 322,274
Balance, shares at Mar. 31, 2018	24,275,147
Issuance of common stock and warrants	$ 6,000	8,844,000		8,850,000
Issuance of common stock and warrants, shares	6,000,000
Shares issued for Summit Healthtech acquisition	$ 6,000	8,994,000		9,000,000
Shares issued for Summit Healthtech acquisition, shares	6,000,000
Fair value of vested restricted common stock		320,642		320,642
Fair value of vested stock options		624,011		624,011
Fair value of common stock issued for services	$ 205	315,845		316,050
Fair value of common stock issued for services, shares	205,000
Net Loss			(3,564,587)	(3,564,587)
Balance at Dec. 31, 2018	$ 36,280	41,441,633	(25,609,523)	15,868,390
Balance, shares at Dec. 31, 2018	36,480,147
Balance at Sep. 30, 2018	$ 24,483	23,953,408	(24,400,952)	(423,061)
Balance, shares at Sep. 30, 2018	24,683,481
Issuance of common stock and warrants	$ 5,667	8,344,333		8,350,000
Issuance of common stock and warrants, shares	5,666,666
Shares issued for Summit Healthtech acquisition	$ 6,000	8,994,000		9,000,000
Shares issued for Summit Healthtech acquisition, shares	6,000,000
Fair value of vested restricted common stock		106,881		106,881
Fair value of vested stock options		(159,659)		(159,659)
Fair value of common stock issued for services	$ 130	202,670		202,800
Fair value of common stock issued for services, shares	130,000
Net Loss			(1,208,571)	(1,208,571)
Balance at Dec. 31, 2018	$ 36,280	41,441,633	(25,609,523)	15,868,390
Balance, shares at Dec. 31, 2018	36,480,147
Balance at Mar. 31, 2019	$ 52,090	47,150,489	(42,181,503)	5,021,076
Balance, shares at Mar. 31, 2019	52,290,147
Fair value of vested stock options		492,554		492,554
Cancellation of shares	$ (1,450)	1,450
Cancellation of shares, shares	(1,450,000)
Net Loss			(3,614,024)	(3,614,024)
Balance at Dec. 31, 2019	$ 50,640	47,644,493	(45,795,527)	1,899,606
Balance, shares at Dec. 31, 2019	50,840,147
Balance at Sep. 30, 2019	$ 50,640	47,502,211	(45,000,232)	2,552,619
Balance, shares at Sep. 30, 2019	50,840,147
Fair value of vested stock options		142,282		142,282
Net Loss			(795,295)	(795,295)
Balance at Dec. 31, 2019	$ 50,640	$ 47,644,493	$ (45,795,527)	$ 1,899,606
Balance, shares at Dec. 31, 2019	50,840,147

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from Operating Activities
Net loss	$ (3,614,024)	$ (3,564,587)
Net loss from discontinued operations	714,827	516,238
Net loss from continuing operations	(2,899,197)	(3,048,349)
Adjustments to reconcile net loss to net cash used in operating activities
Fair value of vested stock options	492,554	624,011
Fair value of vested restricted common stock		320,642
Fair value of common stock issued for services		316,050
Operating lease expense	93,845
Change in fair value of derivative liability	(35,625)	(100,559)
Changes in operating assets and liabilities:
Prepaid expense and other current assets	24,598	(20,256)
Prepaid expense, related party		2,600
Deposits	(10,000)
Accounts payable and accrued liabilities	292,521	151,387
Accounts payable - related party	(5,200)	5,200
Operating lease liability	(97,954)
Net cash used in operating activities- continuing operations	(2,144,458)	(1,749,274)
Net cash used in operating activities- discontinued operations	(714,883)	(686,390)
Net cash used in operating activities	(2,859,341)	(2,435,664)
Cash flows from Investing Activities
Cash provided by continuing operations
Cash provided by discontinued operations		141,545
Net cash provided by investing activities		141,545
Cash flows from Financing Activities
Advance from unrelated party		250,000
Proceeds from sale of common stock and warrants		8,850,000
Net cash provided by financing activities		9,100,000
Net increase (decrease) in cash	(2,859,341)	6,805,881
Cash and cash equivalents - beginning of period	5,982,741	656,290
Cash and cash equivalents - end of period	3,123,400	7,462,171
Supplemental disclosure of cash flow information:
Cash paid during the period for: Interest
Cash paid during the period for: Income taxes
Supplemental non-cash investing and financing activities:
Initial recognition of operating lease right-of-use assets and operating lease obligations upon adoption of new lease accounting standard	248,425
Cancellation of shares	1,450
Current assets		168,046
Fixed assets		12,269
Costs in excess of net assets acquired		9,050,000
Current liabilities assumed		$ (230,315)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement of Cash Flows [Abstract]
Fair value of common stock issued in acquisition	$ 9,000,000	$ 9,000,000

Business Operations and Summary

Business Operations and Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Operations and Summary of Significant Accounting Policies	1. BUSINESS OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007. The Company’s fiscal year end is March 31. In 2015, the Company developed a new class of cannabinoids known as cannabosides, which were discovered through application of the Company’s proprietary enzymatic bioprocessing technologies. In 2016, the Company received approvals from the U.S. Drug Enforcement Administration (the “DEA”) and the State of California to initiate studies and manufacturing scale-up at its research and development facilities in order to develop cannabosides. Currently, we do not have any commercial products and have not yet generated any revenues from our cannabinoid prodrug pharmaceuticals. Liquidity The Company is engaged in the research and development of cannabinoid prodrug pharmaceuticals and since we do not have any commercial products currently available in the marketplace, the Company has generated only minimal revenues from sales of products or services. As reflected in the accompanying financial statements, during the nine months ended December 31, 2019, the Company incurred a net loss of $3,614,024 and used $2,859,341 of cash in our operating activities. As of December 31, 2019, we had $3,123,400 of cash on hand, stockholders’ equity of $1,899,606 and had working capital of $1,746,983. Our total expenditures for the year following December 31, 2019, are expected to be approximately $3,000,000, which is comprised of research and development and general operating expenses. Given that we have discretion over the amount of cash that we will invest in research and development and strategic partnership investments, and based on the funds we had available on December 31, 2019, we believe that we have sufficient capital to fund our anticipated operating expenses and investment activity for at least one year from the date that the financial statements are issued. While we believe that our existing cash balances will be sufficient to fund our currently planned level of operations and investment activity in the near term, we will require additional financing to fund further development of our pharmaceutical prodrugs and carry out our business plan. No assurance can be given that any future financing, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company. Basis of Presentation of Unaudited Condensed Financial Information The unaudited condensed financial statements of the Company for the three and nine months ended December 31, 2019 and 2018 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2019 was derived from the Company’s audited financial statements as of and for the year ended March 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on July 15, 2019. These financial statements should be read in conjunction with that report. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities. Leases Prior to April 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases Leases Financial Assets and Liabilities Measured at Fair Value The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. As of December 31, 2019 and March 31, 2019, the Company’s balance sheet includes Level 3 liabilities comprised of the fair value of derivative liabilities of $85 and $35,710, respectively (see Note 5). These derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. The following table sets forth a summary of the changes in the estimated fair value of our derivative liabilities during the nine-month periods ended December 31, 2019 and 2018: Nine months December 31, Nine months December 31, Fair value at beginning of period $ 35,710 $ 153,042 Net change in the fair value of derivative liabilities (35,625 ) 100,559 Fair value at end of period $ 85 $ 52,483 Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the December 31, 2019 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Share-Based Payments The Company issues stock options and warrants, shares of common stock, and equity interests as share-based compensation to employees and non-employees. The Company accounts for its share-based compensation in accordance with FASB ASC 718, Compensation – Stock Compensation In prior periods up to March 31, 2019, the Company accounted for share-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50, Equity - Based Payments to Non-Employees In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Basic and Diluted Loss Per Share Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: Nine months ended December 31, 2019 December 31, 2018 Options 6,546,710 3,456,710 Warrants 1,135,003 1,301,670 Total 7,681,713 4,758,380 Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred. Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326) Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	2. DISCONTINUED OPERATIONS In October 2018, the Company initially issued 6,000,000 shares of the Company’s common stock valued at $9,000,000 in exchange for all of the outstanding common stock of Summit Healthtech, Inc. (renamed Vitality Healthtech, Inc.) and its subsidiary The Control Center, Inc. (collectively, “Summit Healthtech”). The shares were valued at $1.50 per share based on a contemporaneous private placement offering price. Included in the 6,000,000 shares of common stock issued for the acquisition of Summit Healthtech were 1,450,000 shares issued to Dr. Arif Karim, the former owner of The Control Center, Inc. Dr. Karim had entered into an employment agreement with Summit Healthtech, Inc. prior to the acquisition by the Company. The Company accounted for the acquisition of Summit Healthtech as a business combination in accordance ASC 805 “Business Combinations” and made a provisional purchase price allocation to reflect the net assets acquired of $180,315 and the net liabilities assumed of $230,315. The excess of the purchase price over identifiable net assets of $9,550,000 was recorded as goodwill and intangible assets. Subsequent to December 31, 2018, the Company cancelled 1,000,000 shares of the Company’s common stock that had been issued as part of the acquisition and accordingly, the total purchase price was adjusted to $7,500,000 and the excess of the purchase price over identifiable net assets was adjusted to $7,550,000. At March 31, 2019, the Company determined that projected losses for Summit Healthtech indicated that the fair value of Summit Healthtech was below its carrying value, and 100% of the goodwill and intangible assets of $7,550,000 was recorded as an impairment. In addition to the clinical operations of Summit Healthcare, Inc., the Company was engaged in the business of selling research diagnostic testing kits (such business, collectively with the clinical operations of Summit Healthcare, Inc., referred to in this Quarterly Report as, the “Company’s clinical and test kit operations”). In May 2019 the Company decided to close the Company’s clinical and test kit operations. The Company’s clinical and test kit operations meet the discontinued operations criteria and are reported as such in all periods presented on the accompanying condensed consolidated financial statements. During the nine months ended December 31, 2019, costs to close the Company’s clinical and test kit operations, primarily made up of severance and related benefits, totaled approximately $165,000, and are included in loss from discontinued operations. On October 30, 2019, the Company reached a settlement with Dr. Arif Karim, whereby the Company and Dr. Karim released all claims against each other, including any claims under the Executive Employment Agreement between Vitality Healthtech, Inc. and Dr. Karim dated October 12, 2018, and the Share Purchase Agreement by and among The Control Center, Inc., Dr. Karim and Vitality Healthtech, Inc. dated October 12, 2018. In exchange for the releases, the Company paid Dr. Karim $120,000, which is included in the costs to close the Company’s clinical and test kit operations, and the 1,450,000 shares of the Company’s common stock issued to Dr. Karim were cancelled. The following table presents the summarized components of loss from discontinued operations for the Company’s clinical and test kit operations: Three Months Ended December 31, 2019 2018 Revenue $ - $ 94,823 Cost of sales - 313,285 Research and development - 15,870 General and administrative 48,769 193,485 Loss from discontinued operations $ (48,769 ) $ (427,817 ) Nine Months Ended December 31, 2019 2018 Revenue $ 44,698 $ 157,656 Cost of sales 143,232 353,742 Research and development 4,361 43,185 General and administrative 611,932 276,967 Loss from discontinued operations $ (714,827 ) $ (516,238 )

Operating Lease

Operating Lease	9 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Operating Lease	3. OPERATING LEASE The Company has an operating lease agreement for its office space with a remaining lease term of 14 months. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company accounts for the lease and non-lease components of its office lease as a single lease component. Lease expense is recognized on a straight-line basis over the lease term. Under ASC 842, an operating lease right-of-use (“ROU”) asset and liability is recognized at commencement date based on the present value of lease payments over the lease term. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in lease arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The Company’s incremental borrowing rate is a hypothetical rate based on its understanding of what its credit rating would be. The operating lease ROU asset includes any lease payments made and excludes lease incentives. The adoption of ASC 842 did not have a significant impact on our liquidity. The components of lease expense and supplemental cash flow information related to leases for the period are as follows: Three Months December 31, 2019 Lease Cost Operating lease cost (included in general and administrative expenses in the Company’s unaudited condensed statement of operations) $ 44,900 Other Information Cash paid for amounts included in the measurement of lease liabilities for the three months ended December 31, 2019 $ 33,783 Weighted average remaining lease term – operating leases (in years) 1.2 Average discount rate – operating leases 6.0 % The supplemental balance sheet information related to leases for the period is as follows: At December 31, Operating leases Long-term right-of-use asset $ 154,580 Short-term operating lease liability $ 115,852 Long-term operating lease liability 34,619 Total operating lease liabilities $ 150,471 Maturities of the Company’s lease liabilities are as follows: Year Ending March 31 Operating Lease 2020 (remaining 3 months) $ 34,177 2021 128,205 Total lease payments 162,382 Less: Imputed interest/present value discount (11,911 ) Present value of lease liabilities $ 150,471 Lease expenses were $44,990 and $37,092 during the three months ended December 31, 2019 and December 31, 2018, respectively.

Advance

Advance	9 Months Ended
	Dec. 31, 2019
Receivables [Abstract]
Advance	4. ADVANCE In July 2018, we received a payment from a third party in the amount of $296,653. To date, the Company has not confirmed the nature of this payment. We have recorded this payment as an advance and, at December 31, 2019, it is included in current liabilities on the accompanying financial statements.

Derivative Liability

Derivative Liability	9 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	5. DERIVATIVE LIABILITY In May 2015, the Company issued certain warrants which included a fundamental transaction provision that could give rise to an obligation to pay cash to the warrant holder. In addition, the warrants contained an anti-dilution provision that allows for the automatic reset of the exercise price of the warrants upon future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants. As such the Company determined that the warrant fundamental transaction provision and exercise price created a derivative instrument. In accordance with the FASB authoritative guidance, the fair value of the warrants was recognized as a derivative instrument and is re-measured at the end of each reporting period with the change in value reported in the statement of operations. At March 31, 2019, the balance of the derivative liabilities was $35,710. During the nine months ended December 31, 2019, the Company recorded a decrease in derivative liability of $35,625. At December 31, 2019, the balance of the derivative liabilities was $85. At December 31, 2019 and March 31, 2019, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions: December 31, 2019 March 31, 2019 Conversion feature: Risk-free interest rate 1.56 % 2.63 % Expected volatility 221 % 177 % Expected life (in years) .37 year 1.13 years Expected dividend yield - - Fair Value: Warrant liability $ 85 $ 35,710 The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future.

Stock Options

Stock Options	9 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock Options	6. STOCK OPTIONS During the nine months ended December 31, 2019, the Company granted to directors and employees options to purchase an aggregate of 3,250,000 shares of the Company’s common stock with exercise prices of $0.30 to $0.35 per share, that expire ten years from the date of grant, and all have vesting periods of 24 months. The fair value of each option award was estimated on the date of grant using the Black-Scholes-Merton option pricing model based on the following assumptions: (i) volatility rate of 176.50%, (ii) discount rate of 1.73%, (iii) zero expected dividend yield, and (iv) expected life of 6 years, which is the average of the term of the options and their vesting periods. The total fair value of the option grants to employees at their grant dates was approximately $1,026,000. A summary of the Company’s stock option activity during the nine months ended December 31, 2019 is as follows: Shares Weighted Balance outstanding at March 31, 2019 3,456,710 $ 1.46 Granted 3,250,000 0.34 Exercised - Expired - - Cancelled (160,000 ) 1.92 Balance outstanding at December 31, 2019 6,546,710 $ 0.89 Balance exercisable at December 31, 2019 3,246,711 $ 1.24 A summary of the Company’s stock options outstanding and exercisable as of December 31, 2019 is as follows: Number of Options Weighted Average Exercise Price Weighted Average Grant- date Stock Price Options Outstanding, December 31, 2019 750,000 $ 0.30 $ 0.30 2,500,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 517,500 $ 1.50-1.95 $ 1.50-1.950 687,500 $ 2.00 – 2.79 $ 2.00 – 2.79 123,334 $ 3.10 – 3.80 $ 3.10 – 3.80 45,834 $ 4.00 – 4.70 $ 4.00 – 4.70 6,546,710 Options Exercisable, December 31, 2019 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 492,501 $ 1.50-1.95 $ 1.50-1.95 662,500 $ 2.00 – 2.79 $ 2.00 – 2.79 123,334 $ 3.10 – 3.80 $ 3.10 – 3.80 45,834 $ 4.00 – 4.70 $ 4.00 – 4.70 3,246,711 During the nine months ended December 31, 2019, we expensed total stock-based compensation related to stock options of $492,554, and the remaining unamortized cost of the outstanding stock-based awards at December 31, 2019 was approximately $721,000. The remaining unamortized cost will be amortized on a straight-line basis over a weighted average remaining vesting period of one year. At December 31, 2019, the 6,546,710 outstanding stock options had no intrinsic value.

Warrants

Warrants	9 Months Ended
	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Warrants	7. WARRANTS At December 31, 2019, warrants to purchase common shares were outstanding as follows: Shares Weighted Balance at March 31, 2019 1,135,003 $ 2.19 Granted - - Exercised - - Expired - - Balance outstanding and exercisable at December 31, 2019 1,135,003 $ 2.19 At December 31, 2019, the 1,135,003 outstanding warrants had no intrinsic value.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. COMMITMENTS AND CONTINGENCIES SEC Private Investigation On August 19, 2016, the Company filed a resale registration statement on Form S-1 (“Form S-1”) with the SEC to register 2,650,000 shares of our common stock and 7,950,000 shares of our common stock issuable upon exercise of certain warrants. On or about December 10, 2016, we were advised that the Enforcement Division of the SEC (the “Enforcement Division”) was conducting (i) a private investigation (a “Private Investigation”) pursuant to Section 20(a) of the Securities Act and Section 21(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and (ii) an examination under Section 8(e) of the Securities Act (a “Section 8(e) Examination”) with respect to this Form S-1. On or about November 14, 2018, we were advised by the staff of the Enforcement Division that, based on the information the staff had as of such date, it was terminating the Section 8(e) Examination. The Company continues to cooperate in connection with the Private Investigation.

Business Operations and Summa_2

Business Operations and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Liquidity The Company is engaged in the research and development of cannabinoid prodrug pharmaceuticals and since we do not have any commercial products currently available in the marketplace, the Company has generated only minimal revenues from sales of products or services. As reflected in the accompanying financial statements, during the nine months ended December 31, 2019, the Company incurred a net loss of $3,614,024 and used $2,859,341 of cash in our operating activities. As of December 31, 2019, we had $3,123,400 of cash on hand, stockholders’ equity of $1,899,606 and had working capital of $1,746,983. Our total expenditures for the year following December 31, 2019, are expected to be approximately $3,000,000, which is comprised of research and development and general operating expenses. Given that we have discretion over the amount of cash that we will invest in research and development and strategic partnership investments, and based on the funds we had available on December 31, 2019, we believe that we have sufficient capital to fund our anticipated operating expenses and investment activity for at least one year from the date that the financial statements are issued. While we believe that our existing cash balances will be sufficient to fund our currently planned level of operations and investment activity in the near term, we will require additional financing to fund further development of our pharmaceutical prodrugs and carry out our business plan. No assurance can be given that any future financing, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company.
Basis of Presentation of Unaudited Condensed Financial Information	Basis of Presentation of Unaudited Condensed Financial Information The unaudited condensed financial statements of the Company for the three and nine months ended December 31, 2019 and 2018 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2019 was derived from the Company’s audited financial statements as of and for the year ended March 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on July 15, 2019. These financial statements should be read in conjunction with that report.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and assumptions used in the valuation of derivative liabilities and the valuation allowance for deferred tax assets, and the accrual of potential liabilities.
Leases	Leases Prior to April 1, 2019, the Company accounted for leases under ASC 840, Accounting for Leases Leases
Financial Assets and Liabilities Measured at Fair Value	Financial Assets and Liabilities Measured at Fair Value The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. As of December 31, 2019 and March 31, 2019, the Company’s balance sheet includes Level 3 liabilities comprised of the fair value of derivative liabilities of $85 and $35,710, respectively (see Note 5). These derivatives result in Level 3 classification because one or more of the significant inputs are not observable in the market or cannot be derived principally from, or corroborated by, observable market data. The following table sets forth a summary of the changes in the estimated fair value of our derivative liabilities during the nine-month periods ended December 31, 2019 and 2018: Nine months December 31, Nine months December 31, Fair value at beginning of period $ 35,710 $ 153,042 Net change in the fair value of derivative liabilities (35,625 ) 100,559 Fair value at end of period $ 85 $ 52,483
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the December 31, 2019 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.
Share-Based Payments	Share-Based Payments The Company issues stock options and warrants, shares of common stock, and equity interests as share-based compensation to employees and non-employees. The Company accounts for its share-based compensation in accordance with FASB ASC 718, Compensation – Stock Compensation In prior periods up to March 31, 2019, the Company accounted for share-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50, Equity - Based Payments to Non-Employees In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: Nine months ended December 31, 2019 December 31, 2018 Options 6,546,710 3,456,710 Warrants 1,135,003 1,301,670 Total 7,681,713 4,758,380
Research and Development	Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326) Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Business Operations and Summa_3

Business Operations and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Fair Value of Derivative Liabilities	The following table sets forth a summary of the changes in the estimated fair value of our derivative liabilities during the nine-month periods ended December 31, 2019 and 2018: Nine months December 31, Nine months December 31, Fair value at beginning of period $ 35,710 $ 153,042 Net change in the fair value of derivative liabilities (35,625 ) 100,559 Fair value at end of period $ 85 $ 52,483
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: Nine months ended December 31, 2019 December 31, 2018 Options 6,546,710 3,456,710 Warrants 1,135,003 1,301,670 Total 7,681,713 4,758,380

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations for Summit Healthcare	The following table presents the summarized components of loss from discontinued operations for the Company’s clinical and test kit operations: Three Months Ended December 31, 2019 2018 Revenue $ - $ 94,823 Cost of sales - 313,285 Research and development - 15,870 General and administrative 48,769 193,485 Loss from discontinued operations $ (48,769 ) $ (427,817 ) Nine Months Ended December 31, 2019 2018 Revenue $ 44,698 $ 157,656 Cost of sales 143,232 353,742 Research and development 4,361 43,185 General and administrative 611,932 276,967 Loss from discontinued operations $ (714,827 ) $ (516,238 )

Operating Lease (Tables)

Operating Lease (Tables)	9 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Schedule of Lease Expenses	The components of lease expense and supplemental cash flow information related to leases for the period are as follows: Three Months December 31, 2019 Lease Cost Operating lease cost (included in general and administrative expenses in the Company’s unaudited condensed statement of operations) $ 44,900 Other Information Cash paid for amounts included in the measurement of lease liabilities for the three months ended December 31, 2019 $ 33,783 Weighted average remaining lease term – operating leases (in years) 1.2 Average discount rate – operating leases 6.0 %
Schedule of Supplement Related to Lease	The supplemental balance sheet information related to leases for the period is as follows: At December 31, Operating leases Long-term right-of-use asset $ 154,580 Short-term operating lease liability $ 115,852 Long-term operating lease liability 34,619 Total operating lease liabilities $ 150,471
Schedule of Maturities of Lease Liabilities	Maturities of the Company’s lease liabilities are as follows: Year Ending March 31 Operating Lease 2020 (remaining 3 months) $ 34,177 2021 128,205 Total lease payments 162,382 Less: Imputed interest/present value discount (11,911 ) Present value of lease liabilities $ 150,471

Derivative Liability (Tables)

Derivative Liability (Tables)	9 Months Ended
	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Valuation Assumptions for Derivative Liabilities	At December 31, 2019 and March 31, 2019, the derivative liabilities were valued using a probability weighted Black-Scholes-Merton pricing model with the following assumptions: December 31, 2019 March 31, 2019 Conversion feature: Risk-free interest rate 1.56 % 2.63 % Expected volatility 221 % 177 % Expected life (in years) .37 year 1.13 years Expected dividend yield - - Fair Value: Warrant liability $ 85 $ 35,710

Stock Options (Tables)

Stock Options (Tables)	9 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of the Company’s stock option activity during the nine months ended December 31, 2019 is as follows: Shares Weighted Balance outstanding at March 31, 2019 3,456,710 $ 1.46 Granted 3,250,000 0.34 Exercised - Expired - - Cancelled (160,000 ) 1.92 Balance outstanding at December 31, 2019 6,546,710 $ 0.89 Balance exercisable at December 31, 2019 3,246,711 $ 1.24
Schedule of Stock Options Outstanding and Exercisable	A summary of the Company’s stock options outstanding and exercisable as of December 31, 2019 is as follows: Number of Options Weighted Average Exercise Price Weighted Average Grant- date Stock Price Options Outstanding, December 31, 2019 750,000 $ 0.30 $ 0.30 2,500,000 $ 0.35 $ 0.35 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 517,500 $ 1.50-1.95 $ 1.50-1.950 687,500 $ 2.00 – 2.79 $ 2.00 – 2.79 123,334 $ 3.10 – 3.80 $ 3.10 – 3.80 45,834 $ 4.00 – 4.70 $ 4.00 – 4.70 6,546,710 Options Exercisable, December 31, 2019 1,664,542 $ 0.50 $ 0.50 128,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 492,501 $ 1.50-1.95 $ 1.50-1.95 662,500 $ 2.00 – 2.79 $ 2.00 – 2.79 123,334 $ 3.10 – 3.80 $ 3.10 – 3.80 45,834 $ 4.00 – 4.70 $ 4.00 – 4.70 3,246,711

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrants Activity	At December 31, 2019, warrants to purchase common shares were outstanding as follows: Shares Weighted Balance at March 31, 2019 1,135,003 $ 2.19 Granted - - Exercised - - Expired - - Balance outstanding and exercisable at December 31, 2019 1,135,003 $ 2.19

Business Operations and Summa_4

Business Operations and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Apr. 02, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Mar. 31, 2018
Net loss		$ (795,295)	$ (1,208,571)	$ (3,614,024)	$ (3,564,587)
Net cash used in operating activities				(2,859,341)	(2,435,664)
Cash on hand		3,123,400		3,123,400			$ 5,982,741
Stockholders' equity		1,899,606	$ 15,868,390	1,899,606	$ 15,868,390	$ 2,552,619	5,021,076	$ (423,061)	$ 322,274
Working capital		1,746,983		1,746,983			4,998,414
Total expected expenditure for operating expenses and investment activity				3,000,000
Operating lease, right-of-use asset		154,580		154,580
Lease liabilities for operating leases		150,471		150,471
Fair value of derivative liabilities		$ 85		$ 85			$ 35,710
Accounting Standards Update 2016-02 [Member]
Operating lease, right-of-use asset	$ 248,425
Lease liabilities for operating leases	248,425
Cumulative-effect adjustment to accumulated deficit	$ 0

Business Operations and Summa_5

Business Operations and Summary of Significant Accounting Policies - Schedule of Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Fair value at beginning of period			$ 35,710	$ 153,042
Net change in the fair value of derivative liabilities	$ (1,711)	$ (162,908)	(35,625)	(100,559)
Fair value at end of period	$ 85	$ 52,483	$ 85	$ 52,483

Business Operations and Summa_6

Business Operations and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive securities excluded from computation of earnings per share	7,681,713	4,758,380
Options [Member]
Antidilutive securities excluded from computation of earnings per share	6,546,710	3,456,710
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	1,135,003	1,301,670

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Feb. 01, 2019	Oct. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
Common stock, shares issued, value				$ 8,350,000		$ 8,850,000
Number of shares cancelled					1,450,000
Severance and related benefits			$ 241,840	$ 96,340	$ 864,849	$ 1,162,011
Dr. Karim [Member]
Cost of disposal paid					120,000
Clinical and Test Kit Operations [Member]
Severance and related benefits					$ 165,000
Summit Healthtech Inc [Member] | Dr Arif Karim [Member]
Common stock, shares issued		1,450,000
Summit Healthtech [Member]
Common stock, shares issued		6,000,000
Common stock, shares issued, value		$ 9,000,000
Business combination, net assets acquired		180,315
Business combination, net liabilities assumed		230,315
Business combination, goodwill and intangible assets		$ 9,550,000
Number of shares cancelled	1,000,000
Business combination, purchase price	$ 7,500,000
Business combination, purchase price adjusted	$ 7,550,000
Business combination, goodwill and intangible assets percentage							100.00%
Business combination, impairment loss							$ 7,550,000

Discontinued Operations - Sched

Discontinued Operations - Schedule of Discontinued Operations for Summit Healthcare (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Revenue		$ 94,823	$ 44,698	$ 157,656
Cost of sales		313,285	143,232	353,742
Research and development		15,870	4,361	43,185
General and administrative	48,769	193,485	611,932	276,967
Loss from discontinued operations	$ (48,769)	$ (427,817)	$ (714,827)	$ (516,238)

Operating Lease (Details Narra

Operating Lease (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating lease remaining lease term	14 months
Lease expenses	$ 93,845
Operating Lease Agreement [Member]
Lease expenses	$ 44,990	$ 37,092

Operating Lease - Schedule of L

Operating Lease - Schedule of Lease Expenses (Details)	9 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Operating lease cost (included in general and administrative expenses in the Company's unaudited condensed statement of operations)	$ 44,900
Cash paid for amounts included in the measurement of lease liabilities	$ 33,783
Weighted average remaining lease term - operating leases (in years)	1 year 2 months 12 days
Average discount rate - operating leases	6.00%

Operating Lease - Schedule of S

Operating Lease - Schedule of Supplement Related to Lease (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Leases [Abstract]
Operating leases: Long-term right-of-use asset	$ 154,580
Operating leases: Short-term operating lease liability	115,852
Operating leases: Long-term operating lease liability	34,619
Operating leases: Total operating lease liabilities	$ 150,471

Operating Lease - Schedule of M

Operating Lease - Schedule of Maturities of Lease Liabilities (Details)	Dec. 31, 2019USD ($)
Leases [Abstract]
2020 (remaining 3 months)	$ 34,177
2021	128,205
Total lease payments	162,382
Less: Imputed interest/present value discount	(11,911)
Present value of lease liabilities	$ 150,471

Advance (Details Narrative)

Advance (Details Narrative) - USD ($)	Dec. 31, 2019	Mar. 31, 2019	Jul. 31, 2018
Receivables [Abstract]
Advance	$ 296,653	$ 296,653	$ 296,653

Derivative Liability (Details N

Derivative Liability (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liabilities	$ 85	$ 35,710	$ 52,483	$ 153,042
Decrease in derivative liability	$ 35,625

Derivative Liability - Schedule

Derivative Liability - Schedule of Valuation Assumptions for Derivative Liabilities (Details)	9 Months Ended	12 Months Ended
	Dec. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Mar. 31, 2018USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value: Warrant liability	$ 85	$ 35,710	$ 52,483	$ 153,042
Risk-free Interest Rate [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, measurement input	1.56	2.63
Expected Volatility [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, measurement input	221	177
Expected Life [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability, term	4 months 13 days	1 year 1 month 16 days
Expected Dividend Yield [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative liability, measurement input	0	0

Stock Options (Details Narrativ

Stock Options (Details Narrative) - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options to purchase an aggregate	3,250,000
Common stock with exercise prices	$ 0.34
Stock option expiration term	10 years
Stock option granted, vesting periods	24 months
Volatility rate	176.50%
Discount rate	1.73%
Expected life	6 years
Fair value of the option grants	$ 1,026,000
Stock-based compensation expense	492,554	$ 624,011
Unamortized cost of outstanding stock-based awards	$ 721,000
Weighted average remaining vesting period	1 year
Outstanding stock options	6,546,710		3,456,710
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock with exercise prices	$ 0.30
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock with exercise prices	$ 0.35

Stock Options - Summary of Stoc

Stock Options - Summary of Stock Option Activity (Details)	9 Months Ended
	Dec. 31, 2019$ / sharesshares
Share-based Payment Arrangement [Abstract]
Shares Outstanding, Beginning Balance Outstanding | shares	3,456,710
Shares, Granted | shares	3,250,000
Shares, Exercised | shares
Shares, Expired | shares
Shares, Cancelled | shares	(160,000)
Shares Outstanding, Ending Balance | shares	6,546,710
Shares, Balance Exercisable | shares	3,246,711
Weighted Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 1.46
Weighted Average Exercise Price, Granted | $ / shares	0.34
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Expired | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares	1.92
Weighted Average Exercise Price, Outstanding Ending Balance | $ / shares	0.89
Weighted Average Exercise Price, Balance Exercisable | $ / shares	$ 1.24

Stock Options - Schedule of Sto

Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) - $ / shares	9 Months Ended
	Dec. 31, 2019	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	6,546,710	3,456,710
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.34
Number of Options Exercisable	3,246,711
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.30
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.35
Stock Options One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	750,000
Weighted Average Exercise Price, Options Outstanding	$ 0.30
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.30
Number of Options Exercisable	1,664,542
Weighted Average Exercise Price, Options Exercisable	$ 0.50
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.50
Stock Options Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	2,500,000
Weighted Average Exercise Price, Options Outstanding	$ 0.35
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.35
Number of Options Exercisable	128,000
Weighted Average Exercise Price, Options Exercisable	$ 0.96
Weighted Average Grant-date Stock Price, Options Exercisable	$ 0.96
Stock Options Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	1,664,542
Weighted Average Exercise Price, Options Outstanding	$ 0.50
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.50
Number of Options Exercisable	130,000
Weighted Average Exercise Price, Options Exercisable	$ 1
Weighted Average Grant-date Stock Price, Options Exercisable	$ 10
Stock Options Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	128,000
Weighted Average Exercise Price, Options Outstanding	$ 0.96
Weighted Average Grant-date Stock Price, Options Outstanding	$ 0.96
Number of Options Exercisable	492,501
Stock Options Four [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Exercisable	$ 1.50
Weighted Average Grant-date Stock Price, Options Exercisable	1.50
Stock Options Four [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Exercisable	1.95
Weighted Average Grant-date Stock Price, Options Exercisable	$ 1.95
Stock Options Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	130,000
Weighted Average Exercise Price, Options Outstanding	$ 1
Weighted Average Grant-date Stock Price, Options Outstanding	10
Weighted Average Exercise Price, Options Exercisable	662,500
Stock Options Five [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Exercisable	2
Weighted Average Grant-date Stock Price, Options Exercisable	2
Stock Options Five [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Exercisable	2.79
Weighted Average Grant-date Stock Price, Options Exercisable	$ 2.79
Stock Options Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	517,500
Number of Options Exercisable	123,334
Stock Options Six [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 1.50
Weighted Average Grant-date Stock Price, Options Outstanding	1.50
Weighted Average Exercise Price, Options Exercisable	3.10
Weighted Average Grant-date Stock Price, Options Exercisable	3.10
Stock Options Six [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	1.95
Weighted Average Grant-date Stock Price, Options Outstanding	1.950
Weighted Average Exercise Price, Options Exercisable	3.80
Weighted Average Grant-date Stock Price, Options Exercisable	$ 3.80
Stock Options Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	687,500
Number of Options Exercisable	45,834
Stock Options Seven [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 2
Weighted Average Grant-date Stock Price, Options Outstanding	2
Weighted Average Exercise Price, Options Exercisable	4
Weighted Average Grant-date Stock Price, Options Exercisable	4
Stock Options Seven [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	2.79
Weighted Average Grant-date Stock Price, Options Outstanding	2.79
Weighted Average Exercise Price, Options Exercisable	4.70
Weighted Average Grant-date Stock Price, Options Exercisable	$ 4.70
Stock Options Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	123,334
Stock Options Eight [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 3.10
Weighted Average Grant-date Stock Price, Options Outstanding	3.10
Stock Options Eight [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	3.80
Weighted Average Grant-date Stock Price, Options Outstanding	$ 3.80
Stock Options Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding	45,834
Stock Options Nine [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	$ 4
Weighted Average Grant-date Stock Price, Options Outstanding	4
Stock Options Nine [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Exercise Price, Options Outstanding	4.70
Weighted Average Grant-date Stock Price, Options Outstanding	$ 4.70

Warrants (Details Narrative)

Warrants (Details Narrative)	Dec. 31, 2019shares
Warrants [Member]
Outstanding warrants	1,135,003

Warrants - Summary of Warrants

Warrants - Summary of Warrants Activity (Details) - Warrants [Member]	9 Months Ended
	Dec. 31, 2019$ / sharesshares
Number of Shares, Warrants Outstanding, Beginning Balance | shares	1,135,003
Number of Shares, Warrants Granted | shares
Number of Shares, Warrants Exercised | shares
Number of Shares, Warrants Expired | shares
Number of Shares, Warrants Outstanding and Exercisable Ending Balance | shares	1,135,003
Weighted Average Exercise Price, Warrants Outstanding, Beginning Balance | $ / shares	$ 2.19
Weighted Average Exercise Price, Warrants Outstanding, Granted | $ / shares
Weighted Average Exercise Price, Warrants Outstanding, Exercised | $ / shares
Weighted Average Exercise Price, Warrants Outstanding, Expired | $ / shares
Weighted Average Exercise Price, Warrants Outstanding, Outstanding and Exercisable, Ending Balance | $ / shares	$ 2.19

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Aug. 19, 2016shares
Common Stock One [Member]
Common stock issuable upon exercise of certain warrants	2,650,000
Common Stock Two [Member]
Common stock issuable upon exercise of certain warrants	7,950,000